Editorial: Novel drugs targeting hypertension revisited

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 3, 2010, Pages 213-214

  Booz, George W ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ENZYME INHIBITOR; EPOXYICOSATRIENOIC ACID; IPTAKALIM; NITRIC OXIDE DONOR; POTASSIUM CHANNEL; ANTIHYPERTENSIVE AGENT;

ARTERY ENDOTHELIUM; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; DIASTOLIC BLOOD PRESSURE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; HEALTH CARE PERSONNEL; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOXIA; LIFE EXPECTANCY; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SYSTOLIC BLOOD PRESSURE; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION; BLOOD PRESSURE; DRUG DELIVERY SYSTEM; DRUG EFFECT; PATHOPHYSIOLOGY; UNITED STATES;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG DELIVERY SYSTEMS; HUMANS; HYPERTENSION; UNITED STATES;

EID: 77957592493     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181f0d63f     Document Type: Editorial

References (14)

1. Writing Group Members, Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121:e46-e215.
2. Feig PU, Roy S, Cody RJ Antihypertensive drug development: current challenges and future opportunities. J Am Soc Hypertens. 2010;4:163-173.
3. Pan Z, Huang J, Cui W., et al Targeting hypertension with a new ATP-sensitive potassium channel opener iptakalim. J Cardiovasc Pharmacol. 2010;56:215-228.
4. Priviero FB, Webb RC Heme-dependent and independent soluble guanylate cyclase activators and vasodilation. J Cardiovasc Pharmacol. 2010;56:229-233.
5. Imig JD. Targeting epoxides for organ damage in hypertension. J Cardiovasc Pharmacol. 2010 [epub ahead of print].
6. Lee CR, Imig JD, Edin M.L., et al Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J. 2010 [epub ahead of print].
7. Harris TR, Li N, Chiamvimonvat N., et al The potential of soluble epoxide hydrolase inhibition in the treatment of cardiac hypertrophy. Congest Heart Fail. 2008;14:219-224.
8. Loot AE, Fleming I. Cytochrome P450-derived epoxyeicosatrienoic acids and pulmonary hypertension: central role of transient receptor potential (TRP) C6 channels. J Cardiovasc Pharmacol. 2010 [epub ahead of print].
9. Williams JM, Murphy S, Burke M., et al 20-HETE: a new target for the treatment of hypertension. J Cardiovasc Pharmacol.
10. Certíková Chábová V, Walkowska A, Kompanowska-Jezierska E, et al. Combined inhibition of 20- hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. Clin Sci (Lond). 2010;118:617-632.
11. 2/ω-hydroxylase/20-HETE pathways. Circ Res. 2009;104:1399-1409.
12. Thilo F, Loddenkemper C, Berg E., et al Increased TRPC3 expression in vascular endothelium of patients with malignant hypertension. Mod Pathol. 2009;22:426-430.
13. Watanabe H, Murakami M, Ohba T., et al TRP channel and cardiovascular disease. Pharmacol Ther. 2008;118:337-351.
14. Epstein BJ. Improving blood pressure control rates by optimizing combination antihypertensive therapy. Expert Opin Pharmacother. 2010;11:2011-2026.